Key clinical point: Patients with migraine who achieved ≥ 50% reduction in headache days at 6 months (responders) with anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) showed an even greater reduction in the number of days per month with photophobia, phonophobia, and aura ratios.
Major finding: Monthly headache days reduced significantly by 9.4 days/month (P < .001) and 2.2 days/month (P = .004) among responders and non-responders, respectively, with responders having additional significant reductions in photophobia (−19.5%; P < .001), phonophobia (−12.1%; P = .010), and aura (−25.1%; P = .008) ratios. Higher basal photophobia ratios were predictors of increased response rates between months 3 and 6 (incidence risk ratio 0.928; P = .040).
Study details: This prospective observational study included 158 patients with migraine treated with anti-CGRP mAb, of whom 43.7% were responders.
Disclosures: This study did not receive any funding. A Alpuente, E Caronna, M Torres-Ferrús, and P Pozo-Rosich declared receiving honoraria as consultants or speakers from various sources.
Source: Alpuente A et al. Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study. Cephalalgia. 2023;43(8):3331024231177636 (Aug 9). doi: 10.1177/03331024231177636